Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2+ breast cancer

Pain

Volumn 156, Issue 8, 2015, Pages 1424-1432

  Doornebal, Chris W ^a,b   Vrijland, Kim ^a   Hau, Cheei Sing ^a   Coffelt, Seth B ^a   Ciampricotti, Metamia ^a   Jonkers, Jos ^a   De Visser, Karin E ^a   Hollmann, Markus W ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Anesthesia; Breast cancer; Metastasis; Opioids

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MORPHINE; SODIUM CHLORIDE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ANALGESIC ACTIVITY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISTANT METASTASIS; DOSE RESPONSE; DRUG SAFETY; FEMALE; GOOD CLINICAL PRACTICE; HUMAN; IMMUNOCOMPETENT CELL; MASTECTOMY; METASTATIC INVASIVE LOBULAR BREAST CANCER; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; TISSUE INJURY; ANIMAL; COMPLICATION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LUNG CARCINOMA; PAIN; PATHOLOGY; PROTO ONCOGENE; PSYCHOLOGY; TREATMENT OUTCOME; TUMOR INVASION; UDDER;

ANALGESICS, OPIOID; ANIMALS; BREAST NEOPLASMS; CARCINOMA, LOBULAR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENES, ERBB-2; HUMANS; MAMMARY GLANDS, ANIMAL; MICE; MICE, KNOCKOUT; MORPHINE; NEOPLASM INVASIVENESS; PAIN; TREATMENT OUTCOME;

EID: 84935846395     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000136     Document Type: Article

References (50)

1. Afsharimani B, Cabot P, Parat M-O. Morphine and tumor growth and metastasis. Cancer Metastasis Rev 2011;30:225-38.
2. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 2008;109:180-7.
3. BoggioK, NicolettiG, Carlo ED, Cavallo F, Landuzzi L, MelaniC, Giovarelli M, Rossi I, Nanni P, Giovanni CD, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-96.
4. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg 2008;107:325-32.
5. Ciampricotti M, Vrijland K, Hau C-S, Pemovska T, Doornebal CW, Speksnijder EN, Wartha K, Jonkers J, de Visser EK. Development of metastatic HER21 breast cancer is independent of the adaptive immune system. J Pathol 2011;224:56-66.
6. Cummings KC III, Xu F, Cummings LC, Cooper GS. A comparison of epidural analgesia and traditional pain management effects on survival and cancer recurrence after colectomy: a population-based study. Anesthesiology 2012;116:797-806.
7. Dalal S, Bruera E. Access to opioid analgesics and pain relief for patients with cancer. Nat Rev Clin Oncol 2013;10:108-16.
8. Derksen PWB, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006;10:437-49.
9. Doornebal CW, Klarenbeek S, Braumuller TM, Klijn CN, CiampricottiM, Hau C-S, Hollmann MW, Jonkers J, de Visser EK. A preclinical mouse model of invasive lobular breast cancer metastasis. Cancer Res 2013;73:353-63.
10. Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/ pharmacodynamic perspective. AAPS J 2008;10:537-51.
11. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006;105:660-4.
12. Fantozzi A, Christofori G. Mouse models of breast cancer metastasis. Breast Cancer Res 2006;8:212.
13. Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007;97:1523-31.
14. Gach K, Szemraj J, Fichna J, Piestrzeniewicz M, Delbro DS, Janecka A. The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line. Chem Biol Drug Des 2009;74:390-6.
15. Gottschalk A, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, Durieux ME, Nemergut EC. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology 2010; 113:27-34.
16. Gottschalk A, Sharma S, Ford J, Durieux ME, Tiouririne M. The role of the perioperative period in recurrence after cancer surgery. Anesth Analg 2010;110:1636-43.
17. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law P-Y, Yee D, Hebbel RP. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002;62:4491-8.
18. Hatzoglou A, Bakogeorgou E, Castanas E. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur J Pharmacol 1996;296: 199-207.
19. Hatzoglou A, Ouafik L, Bakogeorgou E, Thermos K, Castanas E. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth. Cancer Res 1995;55:5632-6.
20. Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth 2012;109(suppl 1): 17-28.
21. Ismail H, Ho KM, Narayan K, Kondalsamy-Chennakesavan S. Effect of neuraxial anaesthesia on tumour progression in cervical cancer patients treated with brachytherapy: a retrospective cohort study. Br J Anaesth 2010;105:145-9.
22. Jonkers J, Derksen PWB. Modeling metastatic breast cancer in mice. J Mammary Gland Biol Neoplasia 2007;12:191-203.
23. Kampa M, Bakogeorgou E, Hatzoglou A, Damianaki A, Martin P-M, Castanas E. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol 1997; 335:255-65.
24. Koodie L, Ramakrishnan S, Roy S. Morphine suppresses tumor angiogenesis through a HIF-1a/p38MAPK pathway. Am J Pathol 2010; 177:984-97.
25. LamC-F, Chang P-J, Huang Y-S, Sung Y-H, HuangC-C, LinM-W, Liu Y-C, Tsai Y-C. Prolonged use of high-dose morphine impairs angiogenesis and mobilization of endothelial progenitor cells inmice. Anesth Analg 2008;107: 686-92.
26. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the m-opioid receptor in human nonsmall cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology 2012;116:857-67.
27. Maneckjee R, Biswas R, Vonderhaar BK. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res 1990; 50:2234-8.
28. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A 1990; 87:3294-8.
29. Martin JL, Koodie L, Krishnan AG, Charboneau R, Barke RA, Roy S. Chronic morphine administration delays wound healing by inhibiting immune cell recruitment to the wound site. Am J Pathol 2010;176:786-99.
30. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen C-T, Garcia JGN, Salgia R, Moss J, Singleton PA. The novel role of themuopioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011;112:558-67.
31. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, DolleP, Tzavara E, Hanoune J, Roques BP, Kieffer BL. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the m-opioid-receptor gene. Nature 1996;383:819-23.
32. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001; 62:111-23.
33. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105-15.
34. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JRA, Sessler DI. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ 2011;342:d1491.
35. Neeman E, Zmora O, Ben-Eliyahu S. A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin Cancer Res 2012;18:4895-902.
36. Page GG, Beneliyahu S, Liebeskind JC. The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 1994;8:241-50.
37. Page GG, Ben-Eliyahu S, Yirmiya R, Liebeskind JC. Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. PAIN 1993;54:21-8.
38. Roy S, Wang J, Kelschenbach J, Koodie L, Martin J. Modulation of immune function by morphine: implications for susceptibility to infection. J Neuroimmune Pharmacol 2006;1:77-89.
39. Sessler DI. Does regional analgesia reduce the risk of cancer recurrence? A hypothesis. Eur J Cancer Prev 2008;17:269-72.
40. Singleton PA, Lingen MW, Fekete MJ, Garcia JGN, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation. Microvasc Res 2006;72:3-11.
41. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JGN. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol 2007; 37:222-31.
42. Tai L-H, de Souza CT, Belanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitbach CJ, Falls TJ, Kirn DH, Bell JC, Makrigiannis AP, Auer RA. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res 2012;73: 97-107.
43. Tavare AN, Perry NJS, Benzonana LL, Takata M, Ma D. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer 2012;130:1237-50.
44. Tegeder I, Grösch S, Schmidtko A, Häussler A, Schmidt H, Niederberger E, Scholich K, Geisslinger G. G protein-independent g1 cell cycle block and apoptosis with morphine in adenocarcinoma cells involvement of p53 phosphorylation. Cancer Res 2003;63:1846-52.
45. Tsui BCH, Rashiq S, Schopflocher D, Murtha A, Broemling S, Pillay J, Finucane BT. Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Can J Anesth Can Anesth 2009;57: 107-12.
46. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004;11:354-65.
47. Willimsky G, Czeh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, Stein H, Blankenstein T. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 2008;205:1687-700.
48. Bar-Yosef SMD, Melamed RMS, Page GGDNS, Shakhar GMA, Shakhar KMA, Ben-Eliyahu SPD. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology 2001;94: 1066-73.
49. Zhao M, Zhou G, Zhang Y, Chen T, Sun X, Stuart C, Hanley G, Li J, Zhang J, Yin D. b-arrestin2 inhibits opioid-induced breast cancer cell death through Akt and caspase-8 pathways. Neoplasma 2009;56: 108-13.
50. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. PAIN 1983;16:109-10.